- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.95 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x 9YA: 2-{3-([1,1'-biphenyl]-3-yl)-5-(cyclopropylmethyl)-4-[(4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid(Non-covalent)
9YA.2: 25 residues within 4Å:- Chain A: R.106, L.107, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, V.235, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.1, EDO.4, EDO.5
18 PLIP interactions:18 interactions with chain A- Hydrophobic interactions: A:R.106, A:R.106, A:L.107, A:L.109, A:V.110, A:N.138, A:P.139, A:A.238, A:Y.239, A:I.326
- Hydrogen bonds: A:N.138, A:D.141, A:D.141, A:I.142, A:E.192, A:T.248
- Salt bridges: A:R.169, A:H.193
9YA.8: 22 residues within 4Å:- Chain B: Q.100, R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.7, EDO.9
18 PLIP interactions:18 interactions with chain B- Hydrophobic interactions: B:R.106, B:R.106, B:L.109, B:V.110, B:N.138, B:P.139, B:P.139, B:A.238, B:Y.239
- Hydrogen bonds: B:N.138, B:D.141, B:D.141, B:D.141, B:I.142, B:E.192
- Salt bridges: B:R.169, B:H.193
- pi-Cation interactions: B:R.106
9YA.14: 25 residues within 4Å:- Chain C: R.106, L.107, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, V.235, A.238, Y.239, I.242, T.248, L.323, I.326
- Ligands: NAI.13, EDO.16, EDO.17
18 PLIP interactions:18 interactions with chain C- Hydrophobic interactions: C:R.106, C:R.106, C:L.107, C:L.109, C:V.110, C:N.138, C:P.139, C:A.238, C:Y.239, C:I.326
- Hydrogen bonds: C:N.138, C:D.141, C:D.141, C:I.142, C:E.192, C:T.248
- Salt bridges: C:R.169, C:H.193
9YA.20: 22 residues within 4Å:- Chain D: Q.100, R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.19, EDO.21
18 PLIP interactions:18 interactions with chain D- Hydrophobic interactions: D:R.106, D:R.106, D:L.109, D:V.110, D:N.138, D:P.139, D:P.139, D:A.238, D:Y.239
- Hydrogen bonds: D:N.138, D:D.141, D:D.141, D:D.141, D:I.142, D:E.192
- Salt bridges: D:R.169, D:H.193
- pi-Cation interactions: D:R.106
- 16 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 3 residues within 4Å:- Chain A: L.12, L.13, K.14
Ligand excluded by PLIPEDO.4: 4 residues within 4Å:- Chain A: R.106, Y.239, I.242
- Ligands: 9YA.2
Ligand excluded by PLIPEDO.5: 4 residues within 4Å:- Chain A: E.192, T.322, L.323
- Ligands: 9YA.2
Ligand excluded by PLIPEDO.6: 3 residues within 4Å:- Chain A: Y.281, K.305, V.306
Ligand excluded by PLIPEDO.9: 5 residues within 4Å:- Chain B: R.106, Y.239, I.242
- Ligands: 9YA.8, EDO.10
Ligand excluded by PLIPEDO.10: 3 residues within 4Å:- Chain B: Y.239, I.242
- Ligands: EDO.9
Ligand excluded by PLIPEDO.11: 4 residues within 4Å:- Chain B: R.177, E.229, V.230, Q.233
Ligand excluded by PLIPEDO.12: 5 residues within 4Å:- Chain A: L.70
- Chain B: N.164, S.167, R.171, P.272
Ligand excluded by PLIPEDO.15: 3 residues within 4Å:- Chain C: L.12, L.13, K.14
Ligand excluded by PLIPEDO.16: 4 residues within 4Å:- Chain C: R.106, Y.239, I.242
- Ligands: 9YA.14
Ligand excluded by PLIPEDO.17: 4 residues within 4Å:- Chain C: E.192, T.322, L.323
- Ligands: 9YA.14
Ligand excluded by PLIPEDO.18: 3 residues within 4Å:- Chain C: Y.281, K.305, V.306
Ligand excluded by PLIPEDO.21: 5 residues within 4Å:- Chain D: R.106, Y.239, I.242
- Ligands: 9YA.20, EDO.22
Ligand excluded by PLIPEDO.22: 3 residues within 4Å:- Chain D: Y.239, I.242
- Ligands: EDO.21
Ligand excluded by PLIPEDO.23: 4 residues within 4Å:- Chain D: R.177, E.229, V.230, Q.233
Ligand excluded by PLIPEDO.24: 5 residues within 4Å:- Chain C: L.70
- Chain D: N.164, S.167, R.171, P.272
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rai, G. et al., Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J. Med. Chem. (2017)
- Release Date
- 2018-01-17
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
CC
AD
C
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.95 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x 9YA: 2-{3-([1,1'-biphenyl]-3-yl)-5-(cyclopropylmethyl)-4-[(4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid(Non-covalent)
- 16 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Rai, G. et al., Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). J. Med. Chem. (2017)
- Release Date
- 2018-01-17
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
CC
AD
C